A Single-Dose, Open-Label, Extension Study to Evaluate the Sustainability of the Effects of SYN-010 in Patients With Irritable Bowel Syndrome With Constipation

Trial Profile

A Single-Dose, Open-Label, Extension Study to Evaluate the Sustainability of the Effects of SYN-010 in Patients With Irritable Bowel Syndrome With Constipation

Completed
Phase of Trial: Phase II

Latest Information Update: 17 Jun 2017

At a glance

  • Drugs Lovastatin (Primary)
  • Indications Irritable bowel syndrome
  • Focus Therapeutic Use
  • Sponsors Synthetic Biologics
  • Most Recent Events

    • 23 May 2016 According to a Synthetic Biologics media release, results from this trial were presented at Digestive Disease Week (DDW 2016).
    • 23 May 2016 Results published in a Synthetic Biologics media release.
    • 05 May 2016 Detailed data will be presented at the Digestive Disease Week 2016, according to a Synthetic Biologics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top